Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its fourth quarter and full year 2022 financial results on March 1, 2023, after U.S. markets close. The company specializes in developing neurology-focused biopharmaceuticals, particularly for epilepsy. A conference call will be held at 4:30 PM ET the same day, with dial-in numbers provided for both domestic and international callers. Additionally, a live audio webcast will be available in the Investors section of their website, offering a replay option post-event.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its participation in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. A key event will be a fireside chat on February 15, 2023, at 3:00 PM ET, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO.
A live webcast will be available on their website, with a replay posted after the event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found at www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) announced advancements in its XEN1101 Phase 3 epilepsy program, now active in both focal onset seizures and primary generalized tonic clonic seizures. The company is financially robust, expecting to fund its operations until 2026. The X-TOLE2 study for focal seizures is underway, with the newly initiated X-ACKT trial targeting generalized seizures. Data from the X-NOVA study on major depressive disorder is anticipated in Q3 2023, alongside collaboration updates with Neurocrine Biosciences.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 9, 2023, at 7:30 am PT (10:30 am ET), led by President and CEO Ian Mortimer. Investors can access a live webcast of the presentation on the company’s website, with a replay available afterward. Xenon focuses on developing innovative treatments for neurological disorders, particularly epilepsy, aiming to address significant unmet medical needs.
Xenon Pharmaceuticals (Nasdaq:XENE) presented positive interim data from the Phase 2b open-label extension of its XEN1101 clinical trial for focal onset seizures at the American Epilepsy Society (AES 2022). Key findings show sustained seizure reduction of 80%-90%, with 17.5% and 10.5% of patients achieving 6- and 12-month seizure freedom, respectively. XEN1101 was well-tolerated, and the ongoing Phase 3 program aims to confirm these results. The trial included a difficult-to-treat patient population, suggesting robust efficacy that may enhance XEN1101's market potential.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in one-on-one investor meetings and a fireside chat at the Bank of America Securities Biotech SMID Cap Conference 2022. The event will be held virtually on December 7-8, 2022. Ian Mortimer, President and CEO, along with Sherry Aulin, CFO, will present on December 7 at 1:10 pm Eastern Time. A webcast of the presentation will be accessible on the company’s website for later viewing. Xenon Pharmaceuticals focuses on developing innovative therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) has announced that President Ian Mortimer and CFO Sherry Aulin will participate in fireside chats and one-on-one meetings at upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Jefferies London Healthcare Conference on November 17. These presentations aim to engage investors and provide insights into the company’s developments in neurology therapeutics. Additional information can be found on their investors' website.
Xenon Pharmaceuticals has launched its Phase 3 program for XEN1101, initiating the X-TOLE2 clinical trial focused on treating epilepsy. The company maintains a strong financial position with approximately $752 million in cash, ensuring funding for operations through 2026. Despite a significant drop in third-quarter revenue from $8.1 million to $0.1 million due to the end of a collaboration with Neurocrine Biosciences and no milestone payments, R&D expenses have increased to $29.4 million. A conference call to discuss these updates is scheduled for today.
Xenon Pharmaceuticals (NASDAQ:XENE) appointed Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. DiFabio joins during a critical time as the company advances multiple late-stage clinical programs aimed at commercializing epilepsy therapeutics. With extensive experience in the life sciences sector, she previously held senior legal roles at various biopharmaceutical firms, including Biogen and Repertoire Immune Medicines. Her role will focus on enhancing Xenon’s legal framework and supporting its strategic goals in neurology therapeutics.
Xenon Pharmaceuticals has initiated its Phase 3 program for XEN1101 by launching the X-TOLE2 clinical trial, targeted at treating adult patients with focal epilepsy. This follows positive Phase 2b results and successful discussions with the FDA regarding trial design. The X-TOLE2 and its parallel study, X-TOLE3, aim to evaluate XEN1101's efficacy as an adjunctive treatment, involving approximately 360 patients each. Successful outcomes could lead to a New Drug Application submission. The program reflects Xenon's commitment to addressing unmet medical needs in epilepsy treatment.